Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 127 results for hepatitis

  1. How can case-finding for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of hepatitis B and hepatitis C infection are identified and tested?

    for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of...

    Research recommendation
    Published
    9 June 2015

  2. Reducing sexually transmitted infections (NG221)

    This guideline covers interventions to prevent sexually transmitted infections (STIs) in people aged 16 and over. It aims to reduce the transmission of all STIs, including HIV, and includes ways to help increase the uptake of STI testing and vaccines for human papillomavirus (HPV) and hepatitis A and B.

    NICE guideline
    Published
    15 June 2022
    View recommendations

    Sections for NG221

  3. How can the uptake of hepatitis C treatment be improved? What factors influence whether or not specific groups at increased risk will begin and complete hepatitis C treatment?

    uptake of hepatitis C treatment be improved? What factors influence whether or not specific groups at increased risk will begin and...

    Research recommendation
    Published
    9 June 2015

  4. Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TA435)

    NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was received from Gilead, but will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    22 March 2017

    Sections for TA435

  5. Introducing a blood borne virus testing facility within a substance misuse harm reduction service

    A project to introduce hepatitis and HIV blood borne virus testing in a needle exchange and drug treatment

    Shared learning
    Last updated
    16 April 2015

  6. Drug allergy: diagnosis and management (CG183)

    This guideline covers diagnosing and managing drug allergy in all age groups. It aims to make it easier for professionals to tell when someone is having an allergic reaction, by specifying the key signs and patterns to look out for. It also makes recommendations on improving people’s understanding of their drug allergies, and ensuring these are recorded properly in their medical records.

    Clinical guideline
    Published
    3 September 2014
    View recommendations

    Sections for CG183

  7. Long-term safety of tenofovir disoproxil in chronic hepatitis B:- Further research should be undertaken to determine the long-term safety of tenofovir disoproxil, including the risk of clinically significant hypophosphataemia and related bone toxicity, in people with chronic hepatitis B. The cost effectiveness of routine monitoring for phosphate loss and bone disease in people with chronic hepatitis B who are receiving tenofovir disoproxil treatment needs further evaluation.

    Question Long-term safety of tenofovir disoproxil in chronic hepatitis B:- Further research should be undertaken to determine the...

    Research recommendation
    Published
    9 June 2015

  8. Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (MTG27)

    Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C.

    Medical technologies guidance
    Last updated
    17 January 2020
    View recommendations

    Sections for MTG27

  9. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

    Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 July 2010
    View recommendations

    Sections for TA193

  10. Stopping antiviral treatment in HBeAg-negative disease:- Further research should be undertaken to evaluate the clinical and cost effectiveness of hepatitis B surface antigen (HBsAg) quantitative assays in determining treatment duration in hepatitis B e antigen- (HBeAg) negative disease.

    and cost effectiveness of hepatitis B surface antigen (HBsAg) quantitative assays in determining treatment duration in...

    Research recommendation
    Published
    9 June 2015

  11. What are the most effective ways of involving people from groups at increased risk in awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how cost effective are peer mentor programmes at increasing the number of people at increased risk who are tested and treated for hepatitis B and C?

    risk in awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how cost effective...

    Research recommendation
    Published
    9 June 2015

  12. Collaborating with community pharmacists to deliver sexual health services

    Hepatitis B and C testing: people at risk of infection

    Shared learning
    Last updated
    23 May 2019

  13. What cost-effective interventions ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison?

    ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    9 June 2015

  14. How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Question How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come...

    Research recommendation
    Published
    9 June 2015

  15. How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Question How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?...

    Research recommendation
    Published
    9 June 2015